Literature DB >> 2938871

Atrial natriuretic peptide: an endogenous factor enhancing sodium excretion in man.

J Anderson, A Struthers, N Christofides, S Bloom.   

Abstract

For many years experimental evidence has suggested the existence of a circulating factor able to enhance sodium excretion. Very recently peptides with natriuretic activity in experimental animals have been isolated from mammalian and human cardiac tissue. In order to determine whether this natriuretic activity has relevance to man we have studied the effects of an infusion of alpha-human atrial natriuretic peptide (alpha-h-ANP) in normal subjects. Sodium excretion trebled (P = less than 0.005) during the infusion of a calculated dose of 15 pmol of alpha-h-ANP min-1 kg-1 and there was an accompanying diuresis; radioimmunoassay of plasma alpha-h-ANP during the natriuresis indicated a mean peak incremental concentration of 203 +/- 78 (SEM) pmol/l. The infusion of a calculated dose of 1.5 pmol min-1 kg-1 did not affect sodium excretion. There were no haemodynamic changes and no side effects were noted.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938871     DOI: 10.1042/cs0700327

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  16 in total

1.  Ventricular and atrial myocytes of newborn rats synthesise and secrete atrial natriuretic peptide in culture: light- and electron-microscopical localisation and chromatographic examination of stored and secreted molecular forms.

Authors:  C J Hassall; J Wharton; S Gulbenkian; J V Anderson; J Frater; D J Bailey; A Merighi; S R Bloom; J M Polak; G Burnstock
Journal:  Cell Tissue Res       Date:  1988-01       Impact factor: 5.249

Review 2.  Atrial natriuretic peptides: clues to their physiological and clinical importance.

Authors:  D R Singer
Journal:  Postgrad Med J       Date:  1987-01       Impact factor: 2.401

3.  Diuretic treatment in decompensated cirrhosis and congestive heart failure.

Authors:  A L Gerbes; R M Arendt
Journal:  Br Med J (Clin Res Ed)       Date:  1986-07-05

4.  Rebound increase in plasma renin and vasopressin following graded infusions of atrial natriuretic peptide in man.

Authors:  T D Williams; K P Walsh; E Pitts; R Sutton; S L Lightman
Journal:  J Endocrinol Invest       Date:  1988-01       Impact factor: 4.256

5.  Increase in plasma concentrations of cardiodilatin (amino terminal pro-atrial natriuretic peptide) in cardiac failure and during recumbency.

Authors:  L Meleagros; J S Gibbs; M A Ghatei; S R Bloom
Journal:  Br Heart J       Date:  1988-07

6.  Effects of insulin on kidney function and sodium excretion in healthy subjects.

Authors:  P Skøtt; O Hother-Nielsen; N E Bruun; J Giese; M D Nielsen; H Beck-Nielsen; H H Parving
Journal:  Diabetologia       Date:  1989-09       Impact factor: 10.122

7.  Renal effects of atrial natriuretic peptide during dopa-decarboxylase inhibition in patients with essential hypertension.

Authors:  C Fronzaroli; G La Villa; G Strazzulla; M Mannelli; F Franchi
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  The renal, cardiovascular and hormonal actions of human atrial natriuretic peptide in man; effects of indomethacin.

Authors:  I Miyamori; M Ikeda; T Matsubara; S Okamoto; H Koshida; S Yasuhara; T Morise; R Takeda
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

9.  The effect of atrial natriuretic peptide on human isolated resistance arteries.

Authors:  A D Hughes; H Nielsen; P S Sever
Journal:  Br J Pharmacol       Date:  1989-08       Impact factor: 8.739

10.  The renal effects of atrial natriuretic peptide in man are not attenuated by (+)-sulpiride.

Authors:  S Freestone; T M MacDonald; R F Jeffrey; J Brown; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.